PTGS2 and neoplasm: These MØs express CD163 and M2-specific markers (increased expression of FOLR2 and MAF and reduced expression of ActA), and show an upregulated expression of different factors that favour tumour progression (including, among others, IL-10, TGF-β, IL-6, IL-8, IDO1, COX2 and GAL-1).